Free Trial

Acadia Healthcare (ACHC) Financials

Acadia Healthcare logo
$25.73 +0.46 (+1.84%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Acadia Healthcare

Annual Income Statements for Acadia Healthcare

This table shows Acadia Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
113 6.14 200 -176 109 -672 191 273 -22 256 -1,103
Consolidated Net Income / (Loss)
111 4.18 200 -175 110 -669 196 280 -16 264 -1,092
Net Income / (Loss) Continuing Operations
111 4.18 200 57 53 143 208 280 -16 264 -1,092
Total Pre-Tax Income
165 33 237 67 78 184 276 374 -25 342 -1,066
Total Operating Income
271 214 413 252 266 309 360 422 50 458 -926
Total Gross Profit
821 1,269 1,300 774 901 935 1,071 1,217 1,356 1,463 1,492
Total Revenue
1,830 2,853 2,877 1,905 2,008 2,090 2,314 2,610 2,929 3,154 3,313
Operating Revenue
1,830 2,853 2,877 1,905 2,008 2,090 2,314 2,610 2,929 3,154 3,313
Total Cost of Revenue
1,009 1,584 1,577 1,131 1,107 1,155 1,244 1,393 1,572 1,691 1,821
Operating Cost of Revenue
974 1,542 1,536 1,131 1,107 1,155 1,244 1,393 1,572 1,691 1,821
Total Operating Expenses
549 1,055 887 522 635 626 711 795 1,306 1,005 2,418
Selling, General & Admin Expense
323 615 642 354 464 470 529 607 671 743 867
Depreciation Expense
64 135 143 80 88 95 107 118 132 150 189
Other Operating Expenses / (Income)
115 252 77 36 35 37 39 45 47 48 48
Impairment Charge
- 0.00 0.00 0.00 27 4.75 24 0.00 9.79 17 1,008
Restructuring Charge
37 48 24 30 21 12 13 24 62 47 164
Other Special Charges / (Income)
11 4.25 0.81 22 - 7.23 0.00 0.00 384 0.00 142
Total Other Income / (Expense), net
-107 -181 -176 -185 -187 -125 -84 -48 -76 -116 -140
Interest Expense
- - - 185 187 158 102 70 82 116 140
Interest & Investment Income
-107 -181 -176 - 0.00 33 18 21 6.42 0.00 0.00
Income Tax Expense
53 29 37 9.91 25 41 68 94 -9.70 77 26
Net Income / (Loss) Attributable to Noncontrolling Interest
-1.08 -1.97 -0.25 0.26 1.20 2.93 4.93 6.89 6.01 8.87 11
Basic Earnings per Share
$1.65 $0.07 $2.30 ($2.01) $1.24 ($7.65) $2.15 $3.05 ($0.24) $2.79 ($12.16)
Weighted Average Basic Shares Outstanding
68.09M 85.70M 86.95M 87.29M 87.61M 87.88M 88.77M 89.68M 90.95M 91.62M 90.71M
Diluted Earnings per Share
$1.64 $0.07 $2.30 ($2.01) $1.24 ($7.59) $2.10 $2.98 ($0.24) $2.78 ($12.16)
Weighted Average Diluted Shares Outstanding
68.39M 85.97M 87.06M 87.42M 87.82M 88.60M 90.79M 91.56M 90.95M 92.06M 90.71M
Weighted Average Basic & Diluted Shares Outstanding
68.20M 87.80M 86.90M 87.40M 88.49M 89.04M 89.90M 91.31M 92.29M 92.91M 92.21M

Quarterly Income Statements for Acadia Healthcare

This table shows Acadia Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-218 58 76 78 68 33 8.37 30 36 -1,178 4.11
Consolidated Net Income / (Loss)
-216 60 79 81 71 34 9.06 38 38 -1,177 4.46
Net Income / (Loss) Continuing Operations
-216 60 79 81 71 34 9.06 38 38 -1,177 4.46
Total Pre-Tax Income
-287 80 99 106 99 38 13 50 40 -1,169 11
Total Operating Income
-271 98 126 136 128 68 44 85 77 -1,130 49
Total Gross Profit
356 342 351 337 387 349 325 417 389 361 362
Total Revenue
750 743 768 796 816 774 771 869 852 821 829
Operating Revenue
750 743 768 796 816 774 771 869 852 821 829
Total Cost of Revenue
394 400 418 460 428 426 445 452 462 461 467
Operating Cost of Revenue
394 400 418 460 428 426 445 452 462 461 467
Total Operating Expenses
627 244 224 201 259 281 281 332 313 1,491 312
Selling, General & Admin Expense
177 170 173 158 190 194 188 213 211 255 214
Depreciation Expense
33 35 36 36 38 40 47 49 47 46 52
Other Operating Expenses / (Income)
12 12 12 0.00 12 12 12 13 12 12 12
Restructuring Charge
11 35 2.85 6.09 8.25 30 31 64 43 25 22
Other Special Charges / (Income)
394 - 0.00 0.00 0.00 - 3.50 -8.72 0.00 146 13
Total Other Income / (Expense), net
-16 -18 -27 -29 -30 -30 -30 -35 -37 -39 -38
Interest Expense
21 - - 29 30 30 30 35 37 39 38
Income Tax Expense
-72 20 20 26 27 4.48 4.40 12 1.67 7.84 6.50
Net Income / (Loss) Attributable to Noncontrolling Interest
2.19 2.03 2.39 2.34 3.24 0.91 0.69 7.81 2.07 0.28 0.36
Basic Earnings per Share
($2.39) $0.63 $0.84 $0.86 $0.74 $0.35 $0.09 $0.33 $0.40 ($12.98) $0.05
Weighted Average Basic Shares Outstanding
91.17M 90.95M 91.36M 91.63M 91.72M 91.62M 91.65M 90.33M 90.41M 90.71M 90.53M
Diluted Earnings per Share
($2.39) $0.64 $0.83 $0.85 $0.74 $0.36 $0.09 $0.33 $0.40 ($12.98) $0.05
Weighted Average Diluted Shares Outstanding
91.17M 90.95M 92.01M 92.04M 92.19M 92.06M 92.04M 90.44M 90.58M 90.71M 90.86M

Annual Cash Flow Statements for Acadia Healthcare

This table details how cash moves in and out of Acadia Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-83 46 2.98 -14 49 325 -245 -36 2.42 -24 57
Net Cash From Operating Activities
240 361 400 414 333 659 374 381 462 130 132
Net Cash From Continuing Operating Activities
242 372 401 226 183 503 374 0.00 462 130 132
Net Income / (Loss) Continuing Operations
111 4.18 200 57 53 143 208 280 -16 264 -1,092
Consolidated Net Income / (Loss)
111 4.18 200 -175 110 -669 196 280 -16 264 -1,092
Depreciation Expense
64 135 143 80 88 95 107 118 132 150 189
Amortization Expense
6.71 10 9.86 10 12 13 4.07 3.26 3.32 4.09 4.86
Non-Cash Adjustments To Reconcile Net Income
35 216 36 58 48 122 49 -6.76 421 117 1,037
Changes in Operating Assets and Liabilities, net
26 6.53 13 19 -18 130 6.40 -14 -78 -406 -7.57
Net Cash From Investing Activities
-884 -660 -337 -361 -201 -282 1,013 -306 -397 -736 -556
Net Cash From Continuing Investing Activities
-884 -660 -337 -276 -148 -238 0.00 0.00 -397 -736 -556
Purchase of Property, Plant & Equipment
-303 -348 -274 -253 -233 -225 -245 -296 -424 -690 -572
Acquisitions
-575 -683 -18 0.00 -45 0.00 -139 -9.51 -0.35 -54 -8.17
Sale of Property, Plant & Equipment
- - 5.25 0.00 12 0.09 3.49 7.07 29 10 24
Other Investing Activities, net
-5.10 -2.47 -49 -23 13 -13 -33 -7.25 -2.16 -2.98 -0.09
Net Cash From Financing Activities
564 359 -60 -67 -62 -51 -1,637 -111 -63 583 481
Net Cash From Continuing Financing Activities
564 359 -60 -64 -59 -48 0.00 0.00 -63 584 481
Repayment of Debt
-1,378 -1,976 -57 -62 -134 -1,073 -2,581 -114 -56 -73 -1,737
Repurchase of Common Equity
- -8.85 -3.46 -3.41 -1.65 0.18 16 -12 0.00 0.00 -50
Payment of Dividends
- - 0.00 0.00 -0.15 -0.92 -1.59 -1.00 -5.11 -2.97 -3.88
Issuance of Debt
1,618 1,659 0.69 0.83 77 1,025 925 0.00 40 655 2,269
Issuance of Common Equity
331 685 - - - 0.00 4.54 15 -41 5.18 4.41
Other Financing Activities, net
-7.45 - - - - - - - 0.00 0.00 -1.50
Cash Interest Paid
87 161 159 175 173 138 94 66 81 113 125
Cash Income Taxes Paid
- - - - 32 - 79 86 66 28 30

Quarterly Cash Flow Statements for Acadia Healthcare

This table details how cash moves in and out of Acadia Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
-13 0.48 -23 -0.14 4.98 -5.84 15 40 -13 15 25
Net Cash From Operating Activities
138 116 -321 171 163 117 11 134 73 -86 62
Net Cash From Continuing Operating Activities
138 -346 -321 171 163 -13 11 134 73 -86 62
Net Income / (Loss) Continuing Operations
-216 60 79 81 71 34 9.06 38 38 -1,177 4.46
Consolidated Net Income / (Loss)
-216 60 79 81 71 34 9.06 38 38 -1,177 4.46
Depreciation Expense
33 35 36 36 38 40 47 49 47 46 52
Amortization Expense
0.83 0.84 1.02 1.02 1.03 1.03 1.06 1.22 1.24 1.35 1.25
Non-Cash Adjustments To Reconcile Net Income
398 -2.29 22 -7.46 20 83 14 4.34 6.81 1,013 7.14
Changes in Operating Assets and Liabilities, net
-79 23 -459 61 33 -40 -59 41 -21 31 -3.75
Net Cash From Investing Activities
-129 -110 -185 -155 -193 -203 -183 -151 -130 -92 -60
Net Cash From Continuing Investing Activities
-129 287 -185 -155 -193 533 -183 -151 -130 -92 -60
Purchase of Property, Plant & Equipment
-128 -139 -142 -154 -190 -203 -175 -168 -136 -93 -77
Acquisitions
-0.35 - -50 -0.37 -2.83 - -8.59 0.43 - - 0.00
Purchase of Investments
- - 0.00 - - - 0.00 - - - 0.00
Sale of Property, Plant & Equipment
0.01 29 9.06 1.15 0.02 0.21 0.04 17 6.53 0.70 16
Divestitures
- - 0.00 - - - 0.00 - - - 0.00
Other Investing Activities, net
-0.99 -0.23 -0.91 -2.03 -0.00 -0.04 -0.06 -0.05 -0.04 0.06 -0.03
Net Cash From Financing Activities
-21 -5.65 483 -16 35 81 187 57 44 193 24
Net Cash From Continuing Financing Activities
-21 57 484 -17 35 -502 187 57 44 193 24
Repayment of Debt
-20 -5.31 -27 -15 -15 -15 -1,724 -4.11 -4.06 -4.09 -59
Repurchase of Common Equity
0.71 0.86 0.00 - 0.84 0.82 -49 -4.93 -0.24 3.95 -2.74
Payment of Dividends
-1.50 -1.63 -1.02 -0.48 -1.47 - 0.00 -1.99 -1.89 - 0.00
Issuance of Debt
- - 510 - 50 95 1,960 70 45 194 85
Issuance of Common Equity
0.02 0.42 2.28 0.69 0.53 1.68 0.00 - 5.00 -0.59 0.74
Other Financing Activities, net
- - - - - - 0.00 - - - 0.00

Annual Balance Sheets for Acadia Healthcare

This table presents Acadia Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
4,279 6,025 6,425 6,173 6,879 6,499 4,768 4,988 5,359 5,957 5,527
Total Current Assets
295 428 472 450 542 2,523 495 506 596 577 814
Cash & Equivalents
11 57 67 51 100 379 134 98 100 76 133
Accounts Receivable
217 263 297 318 289 274 281 322 361 365 441
Other Current Assets
67 108 107 82 65 61 80 86 134 136 240
Plant, Property, & Equipment, net
1,709 2,704 3,048 3,108 1,500 1,623 1,771 1,952 2,267 2,853 3,111
Total Noncurrent Assets
2,275 2,893 2,905 2,614 4,837 2,353 2,502 2,530 2,496 2,526 1,602
Goodwill
2,128 2,681 2,751 2,396 2,085 2,105 2,200 2,223 2,226 2,265 1,296
Intangible Assets
60 83 87 89 69 69 70 76 73 70 97
Noncurrent Deferred & Refundable Income Taxes
49 3.78 3.73 3.47 3.34 3.21 3.08 2.95 6.66 21 2.53
Other Noncurrent Operating Assets
39 125 63 125 153 176 229 228 190 170 207
Total Liabilities & Shareholders' Equity
4,279 6,025 6,425 6,173 6,879 6,499 4,768 4,988 5,359 5,957 5,527
Total Liabilities
2,588 3,839 3,829 3,810 4,341 4,545 2,185 2,087 2,471 2,766 3,387
Total Current Liabilities
290 343 377 416 464 1,308 405 388 886 578 525
Short-Term Debt
45 35 35 34 44 153 19 21 29 77 28
Accounts Payable
91 80 102 118 90 88 99 105 156 233 150
Accrued Expenses
73 123 141 151 69 178 126 111 532 88 137
Current Employee Benefit Liabilities
81 105 99 113 94 125 138 125 142 155 189
Other Current Liabilities
- - - 0.00 18 104 23 26 26 25 21
Total Noncurrent Liabilities
2,298 3,496 3,452 3,394 3,877 3,236 1,780 1,699 1,585 2,188 2,862
Long-Term Debt
2,195 3,253 3,205 3,159 3,105 2,969 1,479 1,365 1,343 1,880 2,472
Noncurrent Deferred & Payable Income Tax Liabilities
24 79 80 80 23 50 74 93 1.93 84 67
Other Noncurrent Operating Liabilities
79 165 166 154 262 217 111 241 241 224 324
Redeemable Noncontrolling Interest
8.06 18 22 29 33 55 65 88 106 117 192
Total Equity & Noncontrolling Interests
1,683 2,168 2,573 2,333 2,505 1,899 2,517 2,813 2,782 3,074 1,949
Total Preferred & Common Equity
1,683 2,168 2,573 2,333 2,505 1,899 2,517 2,813 2,782 3,074 1,949
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,683 2,168 2,573 2,333 2,505 1,899 2,517 2,813 2,782 3,074 1,949
Common Stock
1,574 2,497 2,518 2,543 2,559 2,581 2,637 2,659 2,650 2,686 2,715
Retained Earnings
214 220 429 253 362 -310 -120 153 132 387 -766

Quarterly Balance Sheets for Acadia Healthcare

This table presents Acadia Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
4,943 5,044 5,150 5,346 5,517 5,678 5,870 6,148 6,308 6,413 5,546
Total Current Assets
522 538 579 703 611 645 652 639 692 748 837
Cash & Equivalents
93 64 112 100 77 77 82 91 131 119 158
Accounts Receivable
316 346 346 363 386 389 384 397 409 431 472
Other Current Assets
112 128 121 241 147 179 186 151 152 198 207
Plant, Property, & Equipment, net
1,909 1,998 2,074 2,146 2,376 2,498 2,680 2,956 3,064 3,092 3,107
Total Noncurrent Assets
2,512 2,508 2,497 2,497 2,530 2,535 2,539 2,553 2,553 2,573 1,603
Goodwill
2,208 2,223 2,223 2,226 2,261 2,261 2,265 2,276 2,276 2,286 1,301
Intangible Assets
76 76 72 74 73 73 73 79 79 85 99
Noncurrent Deferred & Refundable Income Taxes
2.98 2.92 2.89 2.85 2.78 2.74 2.71 23 25 28 2.49
Other Noncurrent Operating Assets
226 206 200 195 193 197 198 174 172 174 200
Total Liabilities & Shareholders' Equity
4,943 5,044 5,150 5,346 5,517 5,678 5,870 6,148 6,308 6,413 5,546
Total Liabilities
2,111 2,114 2,139 2,536 2,542 2,613 2,724 2,974 3,085 3,123 3,378
Total Current Liabilities
401 378 432 865 482 547 610 473 524 518 489
Short-Term Debt
21 21 24 27 61 67 72 16 20 24 33
Accounts Payable
116 126 149 150 156 160 201 204 220 180 142
Accrued Expenses
128 110 122 540 120 159 168 88 105 126 137
Current Employee Benefit Liabilities
110 95 111 122 118 135 141 140 156 166 157
Other Current Liabilities
26 26 26 26 27 27 27 25 23 21 21
Total Noncurrent Liabilities
1,710 1,736 1,706 1,671 2,060 2,067 2,115 2,500 2,561 2,605 2,889
Long-Term Debt
1,379 1,400 1,372 1,350 1,794 1,775 1,805 2,184 2,247 2,285 2,494
Noncurrent Deferred & Payable Income Tax Liabilities
94 93 93 70 16 37 54 81 80 94 77
Other Noncurrent Operating Liabilities
119 244 241 251 250 255 256 235 234 226 318
Redeemable Noncontrolling Interest
88 90 91 98 109 112 115 132 146 170 210
Total Equity & Noncontrolling Interests
2,744 2,840 2,921 2,713 2,866 2,953 3,032 3,042 3,078 3,120 1,958
Total Preferred & Common Equity
2,744 2,840 2,921 2,713 2,866 2,953 3,032 3,042 3,078 3,120 1,958
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
2,744 2,840 2,921 2,713 2,866 2,953 3,032 3,042 3,078 3,120 1,958
Common Stock
2,651 2,620 2,629 2,639 2,658 2,666 2,677 2,693 2,703 2,709 2,720
Retained Earnings
92 219 292 74 208 287 355 348 375 412 -762

Annual Metrics And Ratios for Acadia Healthcare

This table displays calculated financial ratios and metrics derived from Acadia Healthcare's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - - - - - - - - - 92,258,166.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 92,258,166.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - -11.95
Growth Metrics
- - - - - - - - - - -
Revenue Growth
77.50% 55.92% 0.86% -33.80% 5.44% 4.06% 10.74% 12.79% 12.20% 7.69% 5.04%
EBITDA Growth
62.55% 5.25% 57.26% -39.41% 6.68% 14.04% 12.79% 15.56% -65.77% 228.96% -219.57%
EBIT Growth
55.70% -21.07% 92.65% -38.97% 5.47% 16.32% 16.31% 17.51% -88.08% 810.20% -302.03%
NOPAT Growth
59.52% -85.20% 1,181.39% -38.24% -15.92% 33.26% 12.72% 16.49% -88.85% 905.92% -282.81%
Net Income Growth
34.24% -96.25% 4,679.43% -187.92% 162.75% -707.69% 129.22% 43.19% -105.59% 1,788.81% -512.85%
EPS Growth
9.33% -95.73% 3,185.71% -187.39% 161.69% -712.10% 127.67% 41.90% -108.05% 1,258.33% -537.41%
Operating Cash Flow Growth
108.53% 50.36% 10.54% 3.63% -19.60% 97.90% -43.16% 1.63% 21.49% -71.95% 1.70%
Free Cash Flow Firm Growth
-184.17% 21.50% 99.75% 12,931.96% 334.99% -85.57% -181.01% 178.27% -65.82% -957.62% 84.95%
Invested Capital Growth
110.04% 38.15% 6.49% -4.56% -34.46% -1.64% 14.50% 3.10% -0.71% 21.93% -11.12%
Revenue Q/Q Growth
12.54% 7.90% 0.69% -36.56% 2.31% 69.94% 2.31% 3.24% 2.36% 1.01% 1.45%
EBITDA Q/Q Growth
13.31% 6.95% 3.88% -41.25% 12.04% 45.26% 18.34% -2.59% 0.80% -4.08% -259.05%
EBIT Q/Q Growth
13.25% 3.44% 4.41% -39.43% 14.80% 29.68% 24.88% -3.70% -6.97% -6.22% -439.78%
NOPAT Q/Q Growth
12.88% 269.60% 12.28% -46.67% 47.17% 145.42% 22.80% -4.48% -6.97% -4.21% -383.11%
Net Income Q/Q Growth
11.86% 226.62% 16.50% -177.74% 152.17% -749.52% 129.70% -2.90% -27.61% -9.02% -1,018.77%
EPS Q/Q Growth
7.89% -30.00% 17.35% -177.61% 151.24% -771.68% 127.93% -3.87% -4.35% -9.15% -1,130.51%
Operating Cash Flow Q/Q Growth
27.65% 0.98% 7.08% -0.08% -2.50% 11.36% -19.15% 4.30% 0.60% 0.31% -60.61%
Free Cash Flow Firm Q/Q Growth
-8.34% 31.61% -100.74% 110.23% 348.85% 55.72% -112.58% 197.04% -68.65% -15.38% 73.03%
Invested Capital Q/Q Growth
4.19% -8.11% 1.20% -6.30% -34.82% -34.77% 8.94% -1.58% 1.77% 2.65% -17.76%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
44.86% 44.48% 45.19% 40.63% 44.86% 44.76% 46.26% 46.62% 46.31% 46.38% 45.04%
EBITDA Margin
18.68% 12.61% 19.66% 17.99% 18.21% 19.95% 20.32% 20.82% 6.35% 19.40% -22.09%
Operating Margin
14.84% 7.51% 14.35% 13.23% 13.23% 14.79% 15.53% 16.18% 1.72% 14.53% -27.95%
EBIT Margin
14.84% 7.51% 14.35% 13.23% 13.23% 14.79% 15.53% 16.18% 1.72% 14.53% -27.95%
Profit (Net Income) Margin
6.09% 0.15% 6.94% -9.21% 5.48% -32.02% 8.45% 10.73% -0.53% 8.39% -32.96%
Tax Burden Percent
67.66% 12.67% 84.29% -260.38% 140.47% -364.10% 70.92% 74.85% 61.75% 77.36% 102.44%
Interest Burden Percent
60.68% 15.38% 57.36% 26.75% 29.50% 59.47% 76.71% 88.56% -50.37% 74.61% 115.14%
Effective Tax Rate
32.40% 87.33% 15.71% 14.70% 32.00% 22.09% 24.50% 25.15% 0.00% 22.64% 0.00%
Return on Invested Capital (ROIC)
6.34% 0.58% 6.22% 3.81% 3.97% 6.73% 7.13% 7.66% 0.84% 7.68% -13.53%
ROIC Less NNEP Spread (ROIC-NNEP)
1.86% -0.26% 1.59% -8.55% 0.61% -61.61% 2.20% 5.05% -3.13% 1.97% -34.43%
Return on Net Nonoperating Assets (RNNOA)
2.33% -0.37% 2.13% -10.89% 0.53% -36.52% 1.49% 2.55% -1.39% 1.02% -27.43%
Return on Equity (ROE)
8.67% 0.22% 8.35% -7.08% 4.49% -29.79% 8.62% 10.21% -0.54% 8.70% -40.96%
Cash Return on Invested Capital (CROIC)
-64.64% -31.46% -0.07% 8.48% 45.60% 8.38% -6.38% 4.61% 1.56% -12.08% -1.75%
Operating Return on Assets (OROA)
8.37% 4.16% 6.63% 4.00% 4.07% 4.62% 6.38% 8.66% 0.97% 8.10% -16.12%
Return on Assets (ROA)
3.44% 0.08% 3.21% -2.79% 1.69% -10.00% 3.47% 5.74% -0.30% 4.67% -19.02%
Return on Common Equity (ROCE)
8.64% 0.21% 8.28% -7.01% 4.44% -29.20% 8.39% 9.93% -0.52% 8.38% -38.59%
Return on Equity Simple (ROE_SIMPLE)
6.62% 0.19% 7.76% -7.52% 4.40% -35.23% 7.77% 9.96% -0.56% 8.60% 0.00%
Net Operating Profit after Tax (NOPAT)
184 27 348 215 181 241 271 316 35 355 -648
NOPAT Margin
10.03% 0.95% 12.09% 11.28% 9.00% 11.52% 11.73% 12.11% 1.20% 11.24% -19.56%
Net Nonoperating Expense Percent (NNEP)
4.48% 0.84% 4.63% 12.36% 3.35% 68.34% 4.94% 2.61% 3.98% 5.71% 20.90%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 7.53% 0.85% 7.05% -14.57%
Cost of Revenue to Revenue
55.14% 55.52% 54.81% 59.37% 55.14% 55.24% 53.74% 53.38% 53.69% 53.62% 54.96%
SG&A Expenses to Revenue
17.67% 21.57% 22.33% 18.57% 23.08% 22.49% 22.85% 23.27% 22.91% 23.56% 26.17%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
30.02% 36.97% 30.84% 27.41% 31.63% 29.97% 30.72% 30.44% 44.59% 31.85% 72.99%
Earnings before Interest and Taxes (EBIT)
271 214 413 252 266 309 360 422 50 458 -926
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
342 360 566 343 366 417 470 543 186 612 -732
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.66 1.34 1.11 0.97 1.17 2.35 2.17 2.66 2.58 1.20 0.67
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 8.37 0.00 22.07 14.57 14.85 4.98 2.35
Price to Revenue (P/Rev)
2.45 1.02 1.00 1.19 1.47 2.14 2.36 2.87 2.45 1.17 0.40
Price to Earnings (P/E)
39.78 471.48 14.35 0.00 27.01 0.00 28.64 27.42 0.00 14.41 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
2.51% 0.21% 6.97% 0.00% 3.70% 0.00% 3.49% 3.65% 0.00% 6.94% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.71 1.13 1.05 0.99 1.67 2.05 1.72 2.12 2.06 1.12 0.86
Enterprise Value to Revenue (EV/Rev)
3.67 2.15 2.11 2.86 3.00 3.48 3.03 3.40 2.92 1.80 1.17
Enterprise Value to EBITDA (EV/EBITDA)
19.65 17.08 10.72 15.88 16.48 17.44 14.89 16.31 45.95 9.28 0.00
Enterprise Value to EBIT (EV/EBIT)
24.73 28.68 14.68 21.60 22.67 23.53 19.48 20.99 169.79 12.40 0.00
Enterprise Value to NOPAT (EV/NOPAT)
36.59 226.30 17.42 25.32 33.34 30.20 25.81 28.04 242.55 16.02 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
27.93 17.00 15.17 13.14 18.10 11.04 18.71 23.30 18.49 43.80 29.32
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 11.39 2.90 24.24 0.00 46.61 131.48 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.33 1.50 1.25 1.35 1.24 1.60 0.62 0.48 0.48 0.61 1.17
Long-Term Debt to Equity
1.30 1.49 1.24 1.34 1.22 1.52 0.62 0.47 0.46 0.59 1.15
Financial Leverage
1.25 1.41 1.34 1.27 0.86 0.59 0.68 0.50 0.44 0.52 0.80
Leverage Ratio
2.52 2.66 2.60 2.54 2.66 2.98 2.48 1.78 1.79 1.86 2.15
Compound Leverage Factor
1.53 0.41 1.49 0.68 0.79 1.77 1.90 1.58 -0.90 1.39 2.48
Debt to Total Capital
56.99% 60.07% 55.52% 57.48% 55.37% 61.50% 38.46% 32.33% 32.21% 38.01% 53.87%
Short-Term Debt to Total Capital
1.15% 0.64% 0.60% 0.61% 0.77% 3.02% 0.44% 0.50% 0.69% 1.49% 0.61%
Long-Term Debt to Total Capital
55.84% 59.43% 54.93% 56.87% 54.60% 58.48% 38.02% 31.83% 31.52% 36.52% 53.26%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.20% 0.32% 0.38% 0.52% 0.58% 1.09% 1.56% 2.06% 2.48% 2.28% 4.13%
Common Equity to Total Capital
42.81% 39.61% 44.09% 42.00% 44.05% 37.41% 59.98% 65.61% 65.31% 59.71% 42.00%
Debt to EBITDA
6.56 9.14 5.73 9.32 8.61 7.49 3.43 2.55 7.37 3.20 -3.42
Net Debt to EBITDA
6.52 8.98 5.61 9.17 8.34 6.58 3.15 2.37 6.84 3.07 -3.23
Long-Term Debt to EBITDA
6.42 9.04 5.67 9.22 8.49 7.12 3.39 2.51 7.22 3.07 -3.38
Debt to NOPAT
12.21 121.08 9.31 14.86 17.43 12.97 5.95 4.38 38.92 5.52 -3.86
Net Debt to NOPAT
12.15 118.98 9.12 14.63 16.88 11.39 5.45 4.07 36.08 5.30 -3.65
Long-Term Debt to NOPAT
11.96 119.80 9.21 14.70 17.19 12.33 5.88 4.32 38.09 5.30 -3.81
Altman Z-Score
1.75 1.11 1.22 0.86 0.91 1.23 2.22 3.03 2.29 1.67 0.15
Noncontrolling Interest Sharing Ratio
0.31% 0.67% 0.84% 1.03% 1.26% 1.97% 2.66% 2.80% 3.35% 3.67% 5.79%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.02 1.25 1.25 1.08 1.17 1.93 1.22 1.30 0.67 1.00 1.55
Quick Ratio
0.79 0.93 0.97 0.89 0.84 0.50 1.03 1.08 0.52 0.76 1.09
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,871 -1,468 -3.72 478 2,078 300 -243 190 65 -558 -84
Operating Cash Flow to CapEx
79.43% 103.80% 148.58% 163.55% 150.69% 292.97% 155.18% 131.65% 117.13% 19.07% 24.07%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 2.59 11.09 1.90 -2.39 2.73 0.79 -4.79 -0.60
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 2.24 1.78 4.17 3.68 5.46 5.63 1.11 0.94
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.87 0.60 2.74 1.31 1.31 0.82 -4.73 -2.97
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.56 0.55 0.46 0.30 0.31 0.31 0.41 0.54 0.57 0.56 0.58
Accounts Receivable Turnover
10.92 11.89 10.27 6.19 6.62 7.43 8.34 8.65 8.56 8.68 8.22
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.32 1.29 1.00 0.62 0.87 1.34 1.36 1.40 1.39 1.23 1.11
Accounts Payable Turnover
14.41 18.48 17.30 10.28 10.65 12.97 13.35 13.71 12.06 8.70 9.50
Days Sales Outstanding (DSO)
33.42 30.70 35.54 58.93 55.15 49.11 43.75 42.21 42.62 42.05 44.40
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
25.33 19.75 21.10 35.51 34.28 28.15 27.35 26.63 30.28 41.96 38.40
Cash Conversion Cycle (CCC)
8.08 10.96 14.44 23.42 20.87 20.96 16.41 15.59 12.34 0.09 6.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
3,921 5,416 5,768 5,505 3,608 3,549 4,063 4,189 4,159 5,071 4,507
Invested Capital Turnover
0.63 0.61 0.51 0.34 0.44 0.58 0.61 0.63 0.70 0.68 0.69
Increase / (Decrease) in Invested Capital
2,054 1,496 352 -263 -1,897 -59 514 126 -30 912 -564
Enterprise Value (EV)
6,715 6,145 6,062 5,441 6,025 7,272 7,005 8,866 8,548 5,681 3,867
Market Capitalization
4,478 2,896 2,867 2,269 2,942 4,473 5,459 7,489 7,171 3,683 1,309
Book Value per Share
$23.48 $24.77 $29.29 $26.44 $28.29 $21.34 $27.99 $30.92 $30.17 $33.09 $21.13
Tangible Book Value per Share
($7.04) ($6.82) ($3.02) ($1.72) $3.97 ($3.08) $2.75 $5.65 $5.23 $7.95 $6.03
Total Capital
3,932 5,473 5,835 5,556 5,688 5,077 4,197 4,287 4,259 5,148 4,641
Total Debt
2,241 3,288 3,240 3,193 3,149 3,122 1,614 1,386 1,372 1,957 2,500
Total Long-Term Debt
2,195 3,253 3,205 3,159 3,105 2,969 1,595 1,365 1,343 1,880 2,472
Net Debt
2,230 3,231 3,173 3,143 3,050 2,744 1,480 1,288 1,272 1,881 2,367
Capital Expenditures (CapEx)
303 348 269 253 221 225 241 289 395 680 548
Debt-free, Cash-free Net Working Capital (DFCFNWC)
39 63 62 18 23 990 -25 41 -361 0.08 184
Debt-free Net Working Capital (DFNWC)
50 120 129 68 122 1,369 109 139 -261 76 317
Net Working Capital (NWC)
4.53 85 94 34 79 1,215 90 118 -290 -0.43 289
Net Nonoperating Expense (NNE)
72 23 148 390 71 910 76 36 51 90 444
Net Nonoperating Obligations (NNO)
2,230 3,231 3,173 3,143 1,069 1,594 1,480 1,288 1,272 1,881 2,367
Total Depreciation and Amortization (D&A)
70 145 153 91 100 108 111 121 136 154 194
Debt-free, Cash-free Net Working Capital to Revenue
2.11% 2.20% 2.14% 0.93% 1.13% 47.37% -1.08% 1.59% -12.31% 0.00% 5.56%
Debt-free Net Working Capital to Revenue
2.73% 4.20% 4.48% 3.58% 6.09% 65.49% 4.70% 5.33% -8.90% 2.42% 9.58%
Net Working Capital to Revenue
0.25% 2.98% 3.27% 1.79% 3.92% 58.15% 3.90% 4.51% -9.89% -0.01% 8.72%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.65 $0.07 $2.30 ($2.01) $1.24 ($7.65) $2.15 $3.05 ($0.24) $2.79 ($12.16)
Adjusted Weighted Average Basic Shares Outstanding
68.09M 85.70M 86.95M 87.29M 87.61M 87.88M 88.77M 89.68M 90.95M 91.62M 90.71M
Adjusted Diluted Earnings per Share
$1.64 $0.07 $2.30 ($2.01) $1.24 ($7.59) $2.10 $2.98 ($0.24) $2.78 ($12.16)
Adjusted Weighted Average Diluted Shares Outstanding
68.39M 85.97M 87.06M 87.29M 87.82M 88.60M 90.79M 91.56M 90.95M 92.06M 90.71M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($2.01) $1.24 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
87.22M 87.55M 87.95M 88.46M 88.49M 89.04M 89.90M 91.31M 92.29M 92.91M 92.21M
Normalized Net Operating Profit after Tax (NOPAT)
216 187 369 259 214 259 299 334 355 404 272
Normalized NOPAT Margin
11.78% 6.55% 12.83% 13.60% 10.63% 12.41% 12.94% 12.79% 12.11% 12.81% 8.20%
Pre Tax Income Margin
9.00% 1.16% 8.23% 3.54% 3.90% 8.79% 11.92% 14.33% -0.87% 10.84% -32.18%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 1.37 1.42 1.95 3.54 6.06 0.61 3.94 -6.61
NOPAT to Interest Expense
0.00 0.00 0.00 1.16 0.96 1.52 2.67 4.53 0.43 3.05 -4.62
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 -0.01 0.24 0.53 1.16 1.91 -4.19 -1.91 -10.52
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 -0.21 -0.21 0.10 0.30 0.39 -4.38 -2.80 -8.53
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.14% -0.14% 0.81% 0.36% -32.61% 1.12% -0.36%
Augmented Payout Ratio
0.00% 211.83% 1.73% -1.94% 1.64% -0.11% -7.52% 4.54% -315.70% 1.12% -4.94%

Quarterly Metrics And Ratios for Acadia Healthcare

This table displays calculated financial ratios and metrics derived from Acadia Healthcare's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - 92,258,166.00 92,211,777.00
DEI Adjusted Shares Outstanding
- - - - - - - - - 92,258,166.00 92,211,777.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - -12.76 0.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
12.54% 10.00% 9.06% 8.85% 8.70% 4.23% 0.32% 9.19% 4.41% 6.10% 7.57%
EBITDA Growth
-271.85% 1.11% 18.39% 15.00% 170.57% -19.33% -44.48% -21.62% -25.04% -1,096.90% 11.92%
EBIT Growth
-352.30% -3.69% 19.33% 15.58% 147.40% -30.86% -66.17% -37.22% -40.38% -1,760.13% 12.24%
NOPAT Growth
-334.78% 0.39% 22.36% 15.03% 149.03% -18.38% -71.43% -37.26% -21.10% -1,417.33% -32.10%
Net Income Growth
-395.05% -5.37% 18.35% 9.88% 133.11% -43.89% -88.49% -53.06% -46.31% -3,611.11% -50.75%
EPS Growth
-406.41% -1.54% 15.28% 7.59% 130.96% -43.75% -89.16% -61.18% -45.95% -3,705.56% -44.44%
Operating Cash Flow Growth
235.94% 2.43% -823.48% 4.51% 18.33% 0.34% 103.57% -22.00% -55.12% -173.94% 436.12%
Free Cash Flow Firm Growth
95.45% 296.10% -69.79% -500.93% -3,648.20% -924.39% -36.79% -8.46% 38.64% 73.36% 253.38%
Invested Capital Growth
-3.98% -0.71% 10.88% 12.40% 20.88% 21.93% 11.14% 10.99% 10.93% -11.12% -14.13%
Revenue Q/Q Growth
2.60% -1.00% 3.40% 3.64% 2.46% -5.08% -0.48% 12.81% -2.03% -3.54% 0.89%
EBITDA Q/Q Growth
-257.73% 156.86% 21.34% 5.68% -3.21% -35.00% -16.48% 49.17% -7.43% -964.36% 109.51%
EBIT Q/Q Growth
-331.04% 136.32% 28.03% 7.58% -5.26% -47.02% -37.35% 99.63% -10.03% -1,575.38% 104.36%
NOPAT Q/Q Growth
-312.04% 138.77% 36.53% 2.48% -9.63% -35.45% -52.21% 125.04% 13.65% -1,177.73% 102.54%
Net Income Q/Q Growth
-393.04% 127.73% 31.82% 2.60% -11.69% -53.02% -72.97% 318.53% 1.00% -3,172.37% 100.38%
EPS Q/Q Growth
-402.53% 126.78% 29.69% 2.41% -12.94% -51.35% -75.00% 266.67% 21.21% -3,345.00% 100.39%
Operating Cash Flow Q/Q Growth
-15.82% -15.63% -376.25% 153.27% -4.69% -28.46% -90.17% 1,063.23% -45.16% -217.87% 171.30%
Free Cash Flow Firm Q/Q Growth
71.65% 609.51% -454.21% -17.43% -76.85% -12.06% 41.22% 6.89% -0.06% 51.35% 437.81%
Invested Capital Q/Q Growth
-4.86% 1.77% 14.29% 1.57% 2.32% 2.65% 4.18% 1.44% 2.26% -17.76% 0.65%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
47.47% 46.10% 45.64% 47.27% 47.51% 45.03% 42.21% 47.95% 45.73% 43.90% 43.65%
EBITDA Margin
-31.57% 18.13% 21.28% 21.70% 20.49% 14.03% 11.78% 15.57% 14.71% -131.85% 12.42%
Operating Margin
-36.13% 13.26% 16.41% 17.04% 15.75% 8.79% 5.54% 9.80% 9.00% -137.58% 5.95%
EBIT Margin
-36.13% 13.26% 16.41% 17.04% 15.75% 8.79% 5.54% 9.80% 9.00% -137.58% 5.95%
Profit (Net Income) Margin
-28.72% 8.04% 10.26% 10.15% 8.75% 4.33% 1.18% 4.36% 4.50% -143.31% 0.54%
Tax Burden Percent
74.99% 74.73% 79.69% 75.91% 72.41% 88.22% 67.30% 75.87% 95.83% 100.67% 40.72%
Interest Burden Percent
106.01% 81.21% 78.41% 78.50% 76.71% 55.83% 31.58% 58.73% 52.20% 103.47% 22.24%
Effective Tax Rate
0.00% 25.27% 20.31% 24.09% 27.59% 11.78% 32.70% 24.13% 4.17% 0.00% 59.28%
Return on Invested Capital (ROIC)
-17.35% 6.95% 8.66% 8.67% 7.89% 5.30% 2.34% 4.71% 5.40% -66.62% 1.66%
ROIC Less NNEP Spread (ROIC-NNEP)
-19.25% 5.87% 7.28% 7.21% 6.48% 3.62% 1.33% 3.34% 3.64% -84.80% 0.97%
Return on Net Nonoperating Assets (RNNOA)
-9.22% 2.60% 3.86% 3.62% 3.34% 1.88% 0.84% 2.07% 2.25% -67.56% 0.81%
Return on Equity (ROE)
-26.56% 9.55% 12.52% 12.29% 11.23% 7.18% 3.19% 6.79% 7.66% -134.17% 2.47%
Cash Return on Invested Capital (CROIC)
4.97% 1.56% -9.22% -10.31% -10.71% -12.08% -4.88% -5.59% -5.97% -1.75% 2.09%
Operating Return on Assets (OROA)
-20.09% 7.50% 9.30% 9.62% 8.77% 4.90% 3.00% 5.28% 4.78% -79.38% 3.43%
Return on Assets (ROA)
-15.97% 4.55% 5.81% 5.73% 4.87% 2.41% 0.64% 2.35% 2.39% -82.68% 0.31%
Return on Common Equity (ROCE)
-25.69% 9.23% 12.10% 11.88% 10.83% 6.91% 3.06% 6.51% 7.32% -126.40% 2.31%
Return on Equity Simple (ROE_SIMPLE)
-0.45% 0.00% -0.12% 0.13% 9.59% 0.00% 6.40% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-190 74 100 103 93 60 29 65 73 -791 20
NOPAT Margin
-25.29% 9.91% 13.08% 12.93% 11.41% 7.76% 3.73% 7.43% 8.62% -96.31% 2.42%
Net Nonoperating Expense Percent (NNEP)
1.91% 1.08% 1.38% 1.45% 1.41% 1.68% 1.01% 1.37% 1.76% 18.18% 0.70%
Return On Investment Capital (ROIC_SIMPLE)
- 1.77% - - - 1.19% 0.55% 1.21% 1.35% -17.78% 0.45%
Cost of Revenue to Revenue
52.53% 53.90% 54.36% 52.73% 52.49% 54.97% 57.79% 52.05% 54.27% 56.10% 56.35%
SG&A Expenses to Revenue
23.55% 22.93% 22.58% 23.32% 23.33% 25.05% 24.41% 24.49% 24.74% 31.07% 25.79%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
83.60% 32.84% 29.23% 30.23% 31.75% 36.24% 36.68% 38.16% 36.73% 181.48% 37.70%
Earnings before Interest and Taxes (EBIT)
-271 98 126 136 128 68 43 85 77 -1,130 49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-237 135 163 173 167 109 91 135 125 -1,083 103
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.39 2.58 2.55 2.12 1.94 1.20 0.93 0.68 0.73 0.67 1.10
Price to Tangible Book Value (P/TBV)
15.70 14.85 13.74 10.14 8.49 4.98 4.10 2.89 3.05 2.35 3.86
Price to Revenue (P/Rev)
2.27 2.45 2.44 2.05 1.89 1.17 0.89 0.65 0.70 0.40 0.64
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 20.98 14.41 15.02 15.01 21.30 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 4.77% 6.94% 6.66% 6.66% 4.70% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.92 2.06 1.93 1.69 1.58 1.12 0.96 0.82 0.85 0.86 1.04
Enterprise Value to Revenue (EV/Rev)
2.75 2.92 3.07 2.66 2.50 1.80 1.60 1.35 1.42 1.17 1.40
Enterprise Value to EBITDA (EV/EBITDA)
42.57 45.95 43.49 34.81 12.22 9.28 9.38 8.71 10.10 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
145.15 169.79 129.92 91.44 15.96 12.40 13.50 13.48 17.05 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
207.36 242.55 185.60 130.63 21.07 16.02 17.77 17.75 20.30 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
17.09 18.49 95.12 78.27 60.31 43.80 10.94 10.29 13.87 29.32 26.02
Enterprise Value to Free Cash Flow (EV/FCFF)
37.88 131.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 46.24
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.49 0.48 0.62 0.60 0.60 0.61 0.69 0.70 0.70 1.17 1.17
Long-Term Debt to Equity
0.48 0.46 0.60 0.58 0.57 0.59 0.69 0.70 0.69 1.15 1.15
Financial Leverage
0.48 0.44 0.53 0.50 0.52 0.52 0.63 0.62 0.62 0.80 0.84
Leverage Ratio
1.82 1.79 1.79 1.78 1.88 1.86 1.90 1.91 1.91 2.15 2.19
Compound Leverage Factor
1.93 1.45 1.40 1.40 1.44 1.04 0.60 1.12 1.00 2.23 0.49
Debt to Total Capital
32.88% 32.21% 38.41% 37.53% 37.36% 38.01% 40.94% 41.29% 41.24% 53.87% 53.82%
Short-Term Debt to Total Capital
0.63% 0.69% 1.27% 1.36% 1.43% 1.49% 0.30% 0.37% 0.44% 0.61% 0.69%
Long-Term Debt to Total Capital
32.24% 31.52% 37.14% 36.17% 35.93% 36.52% 40.64% 40.92% 40.81% 53.26% 53.13%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
2.33% 2.48% 2.26% 2.28% 2.28% 2.28% 2.46% 2.65% 3.03% 4.13% 4.47%
Common Equity to Total Capital
64.79% 65.31% 59.32% 60.19% 60.36% 59.71% 56.59% 56.06% 55.73% 42.00% 41.71%
Debt to EBITDA
7.46 7.37 8.78 7.87 2.94 3.20 4.08 4.52 5.02 -3.42 -3.51
Net Debt to EBITDA
6.92 6.84 8.41 7.54 2.81 3.07 3.91 4.26 4.76 -3.23 -3.29
Long-Term Debt to EBITDA
7.32 7.22 8.49 7.59 2.83 3.07 4.05 4.48 4.97 -3.38 -3.46
Debt to NOPAT
36.34 38.92 37.46 29.54 5.07 5.52 7.73 9.21 10.09 -3.86 -3.92
Net Debt to NOPAT
33.71 36.08 35.90 28.30 4.85 5.30 7.41 8.67 9.57 -3.65 -3.68
Long-Term Debt to NOPAT
35.64 38.09 36.22 28.47 4.88 5.30 7.67 9.12 9.98 -3.81 -3.87
Altman Z-Score
1.88 2.32 2.42 2.15 1.99 1.46 1.22 1.08 1.12 0.03 0.90
Noncontrolling Interest Sharing Ratio
3.29% 3.35% 3.38% 3.33% 3.56% 3.67% 3.93% 4.09% 4.42% 5.79% 6.41%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.81 0.67 1.27 1.18 1.07 1.00 1.35 1.32 1.44 1.55 1.71
Quick Ratio
0.53 0.52 0.96 0.85 0.76 0.76 1.03 1.03 1.06 1.09 1.29
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-20 103 -366 -430 -760 -852 -501 -466 -467 -227 767
Operating Cash Flow to CapEx
107.67% 105.79% -240.93% 111.80% 85.76% 57.41% 6.57% 88.32% 56.44% -93.30% 102.24%
Free Cash Flow to Firm to Interest Expense
-0.98 0.00 -13.45 -14.74 -25.41 -28.33 -17.16 -13.27 -12.74 -5.79 20.00
Operating Cash Flow to Interest Expense
6.65 0.00 -11.81 5.87 5.45 3.88 0.39 3.80 2.00 -2.20 1.61
Operating Cash Flow Less CapEx to Interest Expense
0.47 0.00 -16.71 0.62 -0.91 -2.88 -5.59 -0.50 -1.54 -4.56 0.04
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.56 0.57 0.57 0.56 0.56 0.56 0.54 0.54 0.53 0.58 0.58
Accounts Receivable Turnover
8.43 8.56 8.17 8.32 8.36 8.68 8.06 8.10 8.02 8.22 7.76
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
1.41 1.39 1.37 1.34 1.29 1.23 1.18 1.16 1.13 1.11 1.11
Accounts Payable Turnover
11.56 12.06 11.34 10.58 9.48 8.70 9.55 9.02 9.16 9.50 10.64
Days Sales Outstanding (DSO)
43.29 42.62 44.68 43.89 43.64 42.05 45.26 45.09 45.54 44.40 47.01
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
31.56 30.28 32.18 34.49 38.48 41.96 38.24 40.45 39.86 38.40 34.29
Cash Conversion Cycle (CCC)
11.73 12.34 12.50 9.40 5.15 0.09 7.02 4.64 5.67 6.00 12.72
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
4,087 4,159 4,754 4,829 4,940 5,071 5,283 5,359 5,480 4,507 4,537
Invested Capital Turnover
0.69 0.70 0.66 0.67 0.69 0.68 0.63 0.63 0.63 0.69 0.69
Increase / (Decrease) in Invested Capital
-169 -30 467 533 853 912 529 531 540 -564 -747
Enterprise Value (EV)
7,855 8,548 9,193 8,142 7,798 5,681 5,059 4,372 4,647 3,867 4,735
Market Capitalization
6,481 7,171 7,305 6,266 5,889 3,683 2,817 2,090 2,287 1,309 2,157
Book Value per Share
$29.43 $30.17 $31.37 $31.83 $32.64 $33.09 $32.74 $33.41 $33.79 $21.13 $21.24
Tangible Book Value per Share
$4.48 $5.23 $5.82 $6.66 $7.47 $7.95 $7.39 $7.84 $8.11 $6.03 $6.05
Total Capital
4,187 4,259 4,831 4,906 5,023 5,148 5,375 5,491 5,599 4,641 4,695
Total Debt
1,377 1,372 1,856 1,841 1,877 1,957 2,201 2,267 2,309 2,500 2,527
Total Long-Term Debt
1,350 1,343 1,794 1,775 1,805 1,880 2,184 2,247 2,285 2,472 2,494
Net Debt
1,277 1,272 1,778 1,764 1,794 1,881 2,109 2,136 2,190 2,367 2,368
Capital Expenditures (CapEx)
128 110 133 153 190 203 175 151 130 92 60
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-234 -361 113 88 32 0.08 91 57 136 184 222
Debt-free Net Working Capital (DFNWC)
-135 -261 190 165 114 76 182 188 254 317 380
Net Working Capital (NWC)
-161 -290 128 99 43 -0.43 166 168 230 289 348
Net Nonoperating Expense (NNE)
26 14 22 22 22 27 20 27 35 386 16
Net Nonoperating Obligations (NNO)
1,277 1,272 1,778 1,764 1,794 1,881 2,109 2,136 2,190 2,367 2,368
Total Depreciation and Amortization (D&A)
34 36 37 37 39 41 48 50 49 47 54
Debt-free, Cash-free Net Working Capital to Revenue
-8.19% -12.31% 3.76% 2.88% 1.03% 0.00% 2.87% 1.76% 4.16% 5.56% 6.58%
Debt-free Net Working Capital to Revenue
-4.71% -8.90% 6.35% 5.41% 3.66% 2.42% 5.76% 5.83% 7.79% 9.58% 11.28%
Net Working Capital to Revenue
-5.64% -9.89% 4.29% 3.23% 1.36% -0.01% 5.25% 5.20% 7.04% 8.72% 10.32%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2.39) $0.63 $0.84 $0.86 $0.74 $0.35 $0.09 $0.33 $0.40 ($12.98) $0.05
Adjusted Weighted Average Basic Shares Outstanding
91.17M 90.95M 91.36M 91.63M 91.72M 91.62M 91.65M 90.33M 90.41M 90.71M 90.53M
Adjusted Diluted Earnings per Share
($2.39) $0.64 $0.83 $0.85 $0.74 $0.36 $0.09 $0.33 $0.40 ($12.98) $0.05
Adjusted Weighted Average Diluted Shares Outstanding
91.17M 90.95M 92.01M 92.04M 92.19M 92.06M 92.04M 90.44M 90.58M 90.71M 90.86M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
92.22M 92.29M 92.77M 92.87M 92.89M 92.91M 92.12M 92.35M 92.26M 92.21M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
94 100 103 108 107 86 53 108 115 -671 59
Normalized NOPAT Margin
12.53% 13.45% 13.37% 13.61% 13.07% 11.13% 6.86% 12.42% 13.45% -81.70% 7.08%
Pre Tax Income Margin
-38.30% 10.77% 12.87% 13.37% 12.08% 4.91% 1.75% 5.75% 4.70% -142.36% 1.32%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-13.07 0.00 4.63 4.65 4.29 2.26 1.46 2.42 2.09 -28.84 1.29
NOPAT to Interest Expense
-9.15 0.00 3.69 3.53 3.11 2.00 0.98 1.84 2.00 -20.19 0.52
EBIT Less CapEx to Interest Expense
-19.24 0.00 -0.27 -0.60 -2.06 -4.50 -4.52 -1.88 -1.45 -31.20 -0.28
NOPAT Less CapEx to Interest Expense
-15.32 0.00 -1.21 -1.72 -3.25 -4.76 -5.00 -2.46 -1.54 -22.55 -1.05
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-28.35% -32.61% -177.65% 121.08% 1.58% 1.12% 1.00% 2.28% 3.26% -0.36% -0.35%
Augmented Payout Ratio
-430.63% -315.70% -177.65% 123.67% 1.57% 1.12% 26.06% 37.67% 48.69% -4.94% -0.71%

Financials Breakdown Chart

Key Financial Trends

Here are the most important trends for Acadia Healthcare (ACHC) across the last four years, based on quarterly income statements, cash flow statements, and balance sheets. The items below are organized to highlight positives first, then neutral observations, and finally potential negatives.

  • Strong mid-2025 revenue momentum: 2025 Q2 operating revenue reached $869.2 million, the strongest quarterly level in the recent period (vs. prior year levels in the low-to-mid $700s millions).
  • Positive quarterly profitability through Q1–Q3 2025: Net income attributable to common shareholders was positive in three consecutive quarters (Q1: +$66.0M, Q2: +$30.1M, Q3: +$36.2M), signaling improving profitability before the year-end items.
  • Operating cash flow showing cash generation in early 2025: Net cash from continuing operating activities was positive in the first three quarters of 2025 (Q1: +$114.8M, Q2: +$133.5M, Q3: +$73.2M).
  • Gross margin staying in the mid‑40s range: 2025 gross margin remained solid in the low-to-mid 40% range (for example, Q4 2025 gross margin around 43.8% and Q3 2025 around 45.8%).
  • Balance sheet supports growth and capitalization: Total assets rose to about $6.41B and total equity around $3.12B by Q3 2025, reflecting a solid capital base to support operations.
  • Financing flexibility evidenced by 2025 debt issuance: In Q4 2025 Acadia issued about $194M in debt, with net financing cash flow of approximately $193.3M for that quarter, indicating access to capital markets when needed.
  • Significant one-time, non-cash items in Q4 2025: Q4 2025 featured a large non-cash adjustment to net income (approximately $1.01B) alongside restructuring and other charges, suggesting material one-off items rather than ongoing operating dynamics.
  • Huge year-end GAAP loss in Q4 2025: Net income attributable to common shareholders plunged to about -$1.178B in Q4 2025 due to year-end charges, overshadowing earlier quarterly strength.
  • Near-term cash flow headwinds in Q4 2025: Net cash from continuing operating activities was negative in Q4 2025 (about -$86.3M), signaling a temporary cash-flow setback despite earlier positives.
  • Debt and liabilities remain sizable concerns: Long-term debt around $2.28B and total liabilities near $3.12B (as of 2025) indicate a relatively high leverage position that could pressure future margins and financial flexibility.
05/06/26 02:04 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Acadia Healthcare's Financials

When does Acadia Healthcare's financial year end?

According to the most recent income statement we have on file, Acadia Healthcare's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Acadia Healthcare's net income changed over the last 10 years?

Acadia Healthcare's net income appears to be on an upward trend, with a most recent value of -$1.09 billion in 2025, falling from $111.48 million in 2015. The previous period was $264.48 million in 2024. Check out Acadia Healthcare's forecast to explore projected trends and price targets.

What is Acadia Healthcare's operating income?
Acadia Healthcare's total operating income in 2025 was -$925.81 million, based on the following breakdown:
  • Total Gross Profit: $1.49 billion
  • Total Operating Expenses: $2.42 billion
How has Acadia Healthcare's revenue changed over the last 10 years?

Over the last 10 years, Acadia Healthcare's total revenue changed from $1.83 billion in 2015 to $3.31 billion in 2025, a change of 81.1%.

How much debt does Acadia Healthcare have?

Acadia Healthcare's total liabilities were at $3.39 billion at the end of 2025, a 22.4% increase from 2024, and a 30.9% increase since 2015.

How much cash does Acadia Healthcare have?

In the past 10 years, Acadia Healthcare's cash and equivalents has ranged from $11.22 million in 2015 to $378.70 million in 2020, and is currently $133.24 million as of their latest financial filing in 2025.

How has Acadia Healthcare's book value per share changed over the last 10 years?

Over the last 10 years, Acadia Healthcare's book value per share changed from 23.48 in 2015 to 21.13 in 2025, a change of -10.0%.



Financial statements for NASDAQ:ACHC last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners